Global Newswire by Notified: M&A

JUNE 24, 2025

Ashleys”), a global pharmaceutical company. (NYSE American: DSS) (“DSS” or the “Company”), a multinational company operating across diverse industries including packaging, wealth management, and biohealth innovation, today announced that its subsidiary, Impact BioMedical Inc.

Mergers 52

Mergers Pharmaceutical Management IT 52

Global Newswire by Notified: M&A

JULY 2, 2025

per share in cash plus one contingent value right (“CVR”) per share for additional aggregate cash payments of up to US$1.19 per CVR if certain milestones as described below are achieved (the “Transaction”).

Pharmaceutical 45

Pharmaceutical Manufacturing Shares IT 45

JD Supra: Mergers

JANUARY 26, 2024

In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024.

M&A 167

M&A Pharmaceutical Business 167

JD Supra: Mergers

SEPTEMBER 4, 2024

August 01, 2024: SEAM Group, a B2B business products and services company that provides safety, reliability, maintenance, and enterprise asset management services in the hospitality, food processing, and pharmaceutical industries, was acquired by ABB for an undisclosed amount.

M&A 167

M&A Hospitality Pharmaceutical Asset Management 167

JD Supra: Mergers

DECEMBER 1, 2023

To that end, the DOJ recently announced its decision to decline to prosecute Lifecore Biomedical, a pharmaceutical and medical device manufacturer, despite evidence that employees of Lifecore’s former US subsidiary bribed Mexican government officials in violation of the Foreign Corrupt Practices Act.

M&A 167

M&A Pharmaceutical Medical Manufacturing 167

JD Supra: Mergers

JANUARY 15, 2025

Integrating AI tools into drug discovery introduces a mix of opportunities and challenges for startups and large pharmaceutical companies. These challenges often center on intellectual property (IP) risks, licensing considerations, M&A due diligence, and documentation practices. By: Fenwick & West LLP

Pharmaceutical 182

Pharmaceutical M&A 182

JD Supra: Mergers

SEPTEMBER 27, 2024

On September 11-12, we had the pleasure of attending the LSX World Congress USA in Boston, where leaders discussed the challenges and opportunities of M&A and partnerships in the pharmaceutical sector. By: A&O Shearman

Pharmaceutical 161

Pharmaceutical M&A 161

Global Newswire by Notified: M&A

JULY 31, 2024

Otsuka Pharmaceutical to acquire Jnana Therapeutics Inc.

Pharmaceutical 89

Pharmaceutical 89

JD Supra: Mergers

APRIL 23, 2024

I moderated a panel, “Structuring Your Life Sciences Transaction: Licensing vs. M&A vs. Asset Sale,” with business development leaders from GSK, Johnson & Johnson, Locust Walk, and Astria Therapeutics.

Pharmaceutical 167

Pharmaceutical M&A Sale Investors 167

Global Newswire by Notified: M&A

AUGUST 28, 2024

Protect Pharmaceutical Corp. PRTT) Finalizes the Merger with KARINCA Logistics.

Pharmaceutical 92

Pharmaceutical Mergers 92

Global Newswire by Notified: M&A

JULY 9, 2025

While Ivers-Lee will remain a separate legal entity, its operations will be integrated into Alvotech’s Technical Operations division, supporting Alvotech’s ambitious plans for growth.

Acquisitions 52

Acquisitions IT Pharmaceutical Manufacturing 52

Global Newswire by Notified: M&A

JULY 8, 2025

Accessibility: Skip TopNav Medvantx Acquires RxS to Broaden Integrated Access & Engagement Solutions for Life Science Combined company will leverage services and technology platforms to offer a broad portfolio of integrated solutions to pharmaceutical and device manufacturers July 08, 2025 08:00 ET | Source: Medvantx, Inc. Medvantx, Inc.

Medical 40

Medical Pharmaceutical Accountant Manufacturing 40

Global Newswire by Notified: M&A

MARCH 20, 2024

Nika Pharmaceuticals, Inc. OTCMKTS: NKPH) announces its merger with Nika BioTechnology, Inc., effective as of March 1, 2024.

Pharmaceutical 89

Pharmaceutical Mergers IT 89

Global Newswire by Notified: M&A

AUGUST 15, 2024

Protect Pharmaceutical Corp. PRTT) Announces New CEO and New Director; Moves to Finalize the Karinca Logistics Merger.

Pharmaceutical 85

Pharmaceutical Mergers 85

Global Newswire by Notified: M&A

JULY 28, 2023

Nasdaq: BIIB) and Reata Pharmaceuticals, Inc. CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. Nasdaq: RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3

Pharmaceutical 76

Pharmaceutical Shares 76

Cooley M&A

OCTOBER 19, 2022

Cooley’s M&A practice has been busy amid the typically slower summer wind down. Steaming through the third quarter, Cooley’s deal flow put us at the top of the Bloomberg, Mergermarket and Refinitiv Q3 M&A league tables. Transfer Traps: Considerations for Dual-Class Companies Contemplating M&A Transactions.

M&A 69

M&A Initial Public Offering Pharmaceutical Medical 69

Global Newswire by Notified: M&A

NOVEMBER 27, 2024

Pharmaceutical contract development and manufacturing firms provide a range of services to small and large pharmaceutical enterprises under a contract. Pharmaceutical contract development and manufacturing firms provide a range of services to small and large pharmaceutical enterprises under a contract.

Pharmaceutical 66

Pharmaceutical Manufacturing 66

The Harvard Law School Forum

JUNE 16, 2023

Posted by Sally Wagner Partin, Sharon Flanagan, and Hannah M. Flanagan are Partners and Hannah M. Related research from the Program on Corporate Governance includes Are M&A Contract Clauses Value Relevant to Target and Bidder Shareholders? Brown is an Associate at Sidley Austin LLP.

M&A 64

M&A Pharmaceutical Acquisitions Valuation 64

Global Newswire by Notified: M&A

SEPTEMBER 12, 2023

12, 2023 (GLOBE NEWSWIRE) -- Valarie Ney , an experienced corporate and M&A attorney, has joined Hunton Andrews Kurth LLP as a partner in Washington, D.C. Ney represents clients from a broad array of industries, including the government contracting, pharmaceutical, healthcare, energy, technology and manufacturing sectors.

M&A 52

M&A Pharmaceutical Healthcare Manufacturing 52

Sun Acquisitions

AUGUST 22, 2024

To mitigate these risks and build more resilient supply chains, companies are increasingly turning to strategic mergers and acquisitions (M&A). To mitigate these risks and build more resilient supply chains, companies are increasingly turning to strategic mergers and acquisitions (M&A).

M&A 52

M&A Management Mergers and Acquisitions Food 52

Global Newswire by Notified: M&A

JULY 1, 2024

Protect Pharmaceutical Corp. Issues Corporate Update.

Pharmaceutical 49

Pharmaceutical Corporation 49

Global Newswire by Notified: M&A

SEPTEMBER 16, 2024

16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” PRINCETON, N.J., ANI” or “the Company”) (Nasdaq: ANIP) today announced the completion of its previously announced acquisition of Alimera Sciences, Inc. Nasdaq: ALIM) (“Alimera”).

Pharmaceutical 49

Pharmaceutical Acquisitions IT 49

Global Newswire by Notified: M&A

OCTOBER 4, 2024

OnKure Announces Closing of Merger with Reneo Pharmaceuticals.

Pharmaceutical 49

Pharmaceutical Mergers 49

Global Newswire by Notified: M&A

JULY 27, 2024

New York, July 27, 2024 (GLOBE NEWSWIRE) -- NEW YORK, July 27, 2024 / GlobeNewswire/-- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.

M&A 45

M&A Mergers Pharmaceutical Shares 45

Global Newswire by Notified: M&A

AUGUST 19, 2024

19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. NEW YORK, Aug. NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. The Merger Agreement was approved by Titan’s board of directors (the “Board”).

Pharmaceutical 53

Pharmaceutical Mergers Shares Business 53

Devensoft

JUNE 19, 2023

Mergers and acquisitions (M&A) constitute intricate and frequently risky transactions with significant implications for stakeholders. That’s why companies need to approach M&A deals with a strategic mindset that minimizes risk and maximizes value.

M&A 52

M&A Mergers and Acquisitions Mergers Management 52

Global Newswire by Notified: M&A

JULY 24, 2023

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3

Pharmaceutical 75

Pharmaceutical Securities 75

Global Newswire by Notified: M&A

AUGUST 24, 2023

DISCLOSURE, Aug. 24, 2023 (GLOBE NEWSWIRE) -- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN.

Pharmaceutical 75

Pharmaceutical 75

Global Newswire by Notified: M&A

SEPTEMBER 16, 2024

16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. PRINCETON, N.J., Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company has initiated closing logistics for the previously announced acquisition of Alimera Sciences, Inc. Nasdaq: ALIM).

Pharmaceutical 45

Pharmaceutical Acquisitions 45

Devensoft

AUGUST 22, 2023

Embracing Innovation in M&A Strategies As the M&A landscape evolves, the call for innovation grows louder. Enter freelance modeling—a dynamic concept that adapts M&A to the fast-paced, unpredictable realm of modern business. In the upcoming sections, we explore how freelance modeling reshapes M&A norms.

M&A 52

M&A Business Mergers and Acquisitions Collaboration 52

Global Newswire by Notified: M&A

JUNE 9, 2024

Selechimica”), an Italian distributor in the pharmaceutical industry. ROTTERDAM, The Netherlands (10 June 2024) – IMCD N.V. IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Italy has signed an agreement to acquire 100% of the shares in Selechimica S.R.L.

Pharmaceutical 52

Pharmaceutical IT Acquisitions Shares 52

How2Exit

MARCH 31, 2024

Get the Insider Tips You Need to Secure Your Deal - Watch Here rn rn About the Guest(s): rn Patrick O'Connell is an experienced mergers and acquisitions (M&A) advisor with a profound depth of knowledge in buying and selling small businesses valued between one to $20 million. b' E200: Buying or Selling a Small Business?

Business 130

Business Mergers and Acquisitions Securities M&A 130

Global Newswire by Notified: M&A

APRIL 23, 2024

a European distributor in the pharmaceutical and nutraceutical industry. ROTTERDAM, The Netherlands 24 April 2024 – IMCD N.V. IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Spain has signed an agreement to acquire 100% of the shares in Cobapharma, S.L.U,

Pharmaceutical 52

Pharmaceutical IT Acquisitions Shares 52

Global Newswire by Notified: M&A

SEPTEMBER 10, 2024

10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” PRINCETON, N.J., ANI” or “the Company”) (Nasdaq: ANIP) today provided an update on the status of the completion of its previously announced acquisition of Alimera Sciences, Inc. Alimera”) (Nasdaq: ALIM).

Pharmaceutical 45

Pharmaceutical Acquisitions IT 45

Global Newswire by Notified: M&A

MARCH 21, 2024

March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired U.S. DEER PARK, Ill.,

Pharmaceutical 45

Pharmaceutical Acquisitions IT 45

Global Newswire by Notified: M&A

JANUARY 13, 2025

Decoys proprietary IMP 3 ACT peptide conjugate drug design and manufacturing platform leverages machine learning (ML) and artificial intelligence (AI) tools

Pharmaceutical 75

Pharmaceutical Mergers Manufacturing 75

Global Newswire by Notified: M&A

JULY 2, 2024

July 02, 2024 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. PALO ALTO, Calif., a Cayman Islands corporation and special purpose acquisition company (Nasdaq: DECA, “SPAC”), today announced the signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur up to $2.0

Pharmaceutical 72

Pharmaceutical Acquisitions Capital Business 72